Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 5.57%18.49M | 9.68%16.78M | 15.34%16.31M | 0.86%65.65M | 13.31%18.69M | 12.94%17.51M | -10.29%15.3M | -11.77%14.14M | 0.58%65.08M | -5.59%16.5M |
Operating revenue | 5.57%18.49M | 9.68%16.78M | 15.34%16.31M | 0.86%65.65M | 13.31%18.69M | 12.94%17.51M | -10.29%15.3M | -11.77%14.14M | 0.58%65.08M | -5.59%16.5M |
Cost of revenue | 6.72%8.69M | 14.13%8.07M | 15.67%7.52M | 6.31%31.03M | 19.88%9.32M | 17.95%8.14M | -7.92%7.07M | -4.89%6.5M | -1.60%29.19M | -4.49%7.77M |
Gross profit | 4.57%9.8M | 5.86%8.71M | 15.06%8.8M | -3.57%34.62M | 7.46%9.38M | 8.92%9.37M | -12.23%8.23M | -16.88%7.65M | 2.43%35.9M | -6.54%8.73M |
Operating expense | 22.89%4.99M | 8.43%4.44M | 6.03%4.6M | 0.26%16.59M | 17.89%4.1M | 0.69%4.06M | -12.43%4.09M | -0.60%4.34M | 9.15%16.55M | -14.36%3.48M |
Selling and administrative expenses | 6.61%2.4M | -2.22%2.6M | 13.00%2.52M | 7.59%9.41M | 18.84%2.27M | 11.74%2.26M | 13.46%2.66M | -10.01%2.23M | -0.48%8.75M | -20.22%1.91M |
Research and development costs | 43.26%2.58M | 28.23%1.84M | -1.33%2.08M | -7.96%7.18M | 16.74%1.83M | -10.39%1.8M | -38.53%1.43M | 11.75%2.11M | 22.45%7.8M | -5.98%1.57M |
Operating profit | -9.44%4.81M | 3.31%4.27M | 26.91%4.19M | -6.84%18.03M | 0.55%5.28M | 16.17%5.31M | -12.03%4.13M | -31.60%3.3M | -2.70%19.35M | -0.53%5.25M |
Net non-operating interest income /expenses | ||||||||||
Other net income /expenses | 65.64%911K | 38.74%659K | 61.38%773K | 758.54%2.11M | 121.09%608K | 937.74%550K | 1,013.46%475K | 1,696.67%479K | 748.28%246K | 6,975.00%275K |
Other non-operating income /expenses | 65.64%911K | 38.74%659K | 61.38%773K | 758.54%2.11M | 121.09%608K | 937.74%550K | 1,013.46%475K | 1,696.67%479K | 748.28%246K | 6,975.00%275K |
Income before tax | -2.39%5.72M | 6.97%4.93M | 31.28%4.97M | 2.77%20.14M | 6.55%5.89M | 26.73%5.86M | -0.82%4.61M | -21.19%3.78M | -1.61%19.59M | 4.76%5.53M |
Income tax | 0.45%668K | 6.27%593K | 44.09%585K | 20.56%2.33M | 40.93%699K | 41.79%665K | 2.57%558K | -3.79%406K | -26.49%1.93M | -31.30%496K |
Net income | -2.75%5.05M | 7.06%4.34M | 29.74%4.38M | 0.83%17.81M | 3.16%5.19M | 25.03%5.2M | -1.27%4.05M | -22.87%3.38M | 2.18%17.66M | 10.48%5.03M |
Net income continuous operations | -2.75%5.05M | 7.06%4.34M | 29.74%4.38M | 0.83%17.81M | 3.16%5.19M | 25.03%5.2M | -1.27%4.05M | -22.87%3.38M | 2.18%17.66M | 10.48%5.03M |
Net income attributable to the company | -2.75%5.05M | 7.06%4.34M | 29.74%4.38M | 0.83%17.81M | 3.16%5.19M | 25.03%5.2M | -1.27%4.05M | -22.87%3.38M | 2.18%17.66M | 10.48%5.03M |
Net income attributable to common stockholders | -2.75%5.05M | 7.06%4.34M | 29.74%4.38M | 0.83%17.81M | 3.16%5.19M | 25.03%5.2M | -1.27%4.05M | -22.87%3.38M | 2.18%17.66M | 10.48%5.03M |
Diluted earnings per share | -3.57%0.27 | 4.55%0.23 | 26.32%0.24 | -1.02%0.97 | 0.00%0.28 | 21.74%0.28 | -4.35%0.22 | -20.83%0.19 | 1.03%0.98 | 12.00%0.28 |
Basic earnings per share | -3.57%0.27 | 4.55%0.23 | 27.78%0.23 | 0.00%0.95 | 0.00%0.27 | 27.27%0.28 | 0.00%0.22 | -25.00%0.18 | 2.15%0.95 | 12.50%0.27 |
Dividend per share | --0 | 0.00%0.25 | --0 | --0.75 | --0 | --0 | --0.25 | --0.5 | ---- | ---- |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |